Aug 20 (Reuters) - Bristol-Myers Squibb Co BMY.N :
* Health Canada approves Daklinza(TM) (daclatasvir) for the treatment of
Chronic Hepatitis C infection across multiple genotypes including genotype 3
* Canada - approval has notice of compliance to treat adult patients with hepatitis c genotypes 1,2 with compensated liver disease
* Source text for Eikon ID:nCNWn37Xla
* Further company coverage BMY.N